NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration’s (FDA) plan to reduce, refine or potentially replace current animal testing ...

The U.S. Food and Drug Administration (FDA) on April 10, 2025, announced a significant policy shift aimed at reducing its reliance on animal testing for drug development and incorporating new approach ...

The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal antibodies and some other drug candidates. Animal testing will be "reduced, ...

Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing ...

Environmental Protection Agency Administrator Lee Zeldin intends to follow through with the first Trump administration's plan to end animal testing. During President Donald Trump's first ...

The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc.

The National Institutes of Health (NIH) is following in the FDA’s footsteps—away from animal testing. The NIH plans to establish a new office meant to develop nonanimal methods for biomedical research ...

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal antibody therapies and other drugs and biological products “with ...

Testing products on animals became an industry standard in the cosmetic, chemical, and pharmaceutical industries nearly a century ago. Since that time, it has become clear that these tests cause ...